0000000000226004

AUTHOR

Andrea Petermann-meyer

showing 2 related works from this author

Outcome comparison of integrated psycho‐oncological care versus unstructured care—Results of a non‐randomised open‐label two‐arm trial

2019

Objective To compare patients' experiences with a systematic, integrated psycho-oncological care (IC) model to experiences with "care as usual" (CAU). Methods To improve patients' knowledge about psychosocial support options and to facilitate use, an IC model was developed by psycho-oncologists and a health insurance company and implemented in one German cancer care facility. Using a parallel, non-randomised design, these patients' experiences were compared to CAU patients. In 2015, both patient groups received questionnaires 6-12 months post-inpatient treatment. Main outcomes were awareness, use and opinion of psycho-oncological care (PC) and anxiety level (Generalized Anxiety Disorder Sca…

AdultMaleHealth Knowledge Attitudes Practicemedicine.medical_specialtyPsycho-OncologyAnxietyYoung Adult03 medical and health sciences0302 clinical medicineAmbulatory careGermanyNeoplasmsSurveys and QuestionnairesmedicineHealth insuranceHumansGeneralized Anxiety Disorder ScaleAgedAged 80 and overResponse rate (survey)business.industryMiddle AgedPatient Acceptance of Health CareMental healthCare facilityOncology030220 oncology & carcinogenesisPhysical therapyAnxietyFemaleOpen labelmedicine.symptombusinessDelivery of Health CareEuropean Journal of Cancer Care
researchProduct

Development Of a Disease Specific Quality Of Life Questionnaire For Patients With Aplastic Anemia and/Or Paroxysmal Nocturnal Hemoglobinuria (QLQ-AA/…

2013

Abstract Introduction Acquired Aplastic Anemia (AA) and Paroxysmal Nocturnal Hemoglobinuria (PNH) are ultra-rare diseases with a yearly incidence 2 to 4 per million (AA) and of 1.3 to 2 per million (PNH. While much is known about pathophysiology and treatment of these interrelated diseases, less is known about patients (pts.) psycho-social issues. Quality of life (QoL) evaluation tools used in all studies for AA and PNH are rather unspecific and were initially designed for cancer patients (e.g. the European Organization of Research and Treatment (EORTC) QLQ-C30). Given the complexity of AA and PNH, the variation in symptoms and different treatment approaches (immunosuppression, bone marrow …

Pediatricsmedicine.medical_specialtybusiness.industryIncidence (epidemiology)ImmunologyCell BiologyHematologymedicine.diseaseBiochemistryFocus grouphumanitiesQuality of lifeHealth careParoxysmal nocturnal hemoglobinuriaMedicineAplastic anemiabusinessPsychosocialDisease burdenBlood
researchProduct